Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-029973
Filing Date
2025-02-28
Accepted
2025-02-28 16:01:40
Documents
132
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K srpt-20241231.htm   iXBRL 10-K 6003350
2 EX-10.67 srpt-ex10_67.htm EX-10.67 1865648
3 EX-19.1 srpt-ex19_1.htm EX-19.1 98485
4 EX-21.1 srpt-ex21_1.htm EX-21.1 8490
5 EX-23.1 srpt-ex23_1.htm EX-23.1 3932
6 EX-31.1 srpt-ex31_1.htm EX-31.1 11125
7 EX-31.2 srpt-ex31_2.htm EX-31.2 11262
8 EX-32.1 srpt-ex32_1.htm EX-32.1 9286
9 EX-32.2 srpt-ex32_2.htm EX-32.2 9254
10 GRAPHIC img79726377_0.jpg GRAPHIC 191328
11 GRAPHIC img79726377_1.jpg GRAPHIC 724223
  Complete submission text file 0000950170-25-029973.txt   26896115

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT srpt-20241231.xsd EX-101.SCH 2676237
135 EXTRACTED XBRL INSTANCE DOCUMENT srpt-20241231_htm.xml XML 4676553
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-14895 | Film No.: 25689866
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)